Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: AL-15469A/AL-38905; AL-15469A/AL-38905 ophthalmic formulation - Alcon Research; MoxiDex Otic; VIGADEXA

Latest Information Update: 12 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alcon
  • Class Anti-inflammatories; Aza compounds; Fluorinated steroids; Pregnadienetriols; Quinolines
  • Mechanism of Action DNA gyrase inhibitors; Glucocorticoid receptor agonists; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Ocular inflammation; Ophthalmic infections
  • Discontinued Corneal disorders; Otitis externa; Otitis media

Most Recent Events

  • 05 Apr 2018 Novartis Pharmaceuticals in collaboration with Alcon Research plans a phase II trial for Otitis Externa in outside the EU/EEA , (EudraCT2018-000641-39)
  • 24 Mar 2014 Alcon withdraws a phase III trial for Ocular inflammation and infection (prevention) in Brazil prior to enrolment (NCT01515826) (Ophthalmic, gel)
  • 17 Feb 2014 Discontinued - Phase-II for Corneal disorders in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top